BNR
Burning Rock Biotech Ltd
16.30$
+0.0%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 32.6% | 35.5% | 31.8% | 29.6% | 28.6% | 29.0% | 26.8% | 27.2% | 24.9% | 22.0% | 27.7% | 27.4% | 25.5% | |
| 67.4% | 64.5% | 68.2% | 70.4% | 71.4% | 71.0% | 73.2% | 72.8% | 75.1% | 78.0% | 72.3% | 72.6% | 74.5% | |
| 65.6% | 60.4% | 52.5% | 47.9% | 38.2% | 41.4% | 30.3% | 33.5% | 31.5% | 27.6% | 25.5% | 23.2% | 27.0% | |
| 93.1% | 100.4% | 78.6% | 68.5% | 25.6% | 66.7% | 23.5% | 21.1% | 24.1% | 60.8% | 26.0% | 27.8% | 34.7% | |
| 207.5% | 201.9% | 168.4% | 152.5% | 101.4% | 137.1% | 84.6% | 80.5% | 87.4% | 87.6% | 89.7% | 85.9% | 87.5% | |
| -140.2% | -137.4% | -100.2% | -82.1% | -30.0% | -37.1% | -11.4% | -7.7% | -12.3% | -9.5% | -17.5% | -13.4% | -13.0% | |
| – | – | – | – | 0.0% | – | 0.0% | – | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| -136.8% | -133.1% | -96.6% | -79.6% | -27.6% | -60.3% | -10.0% | -6.4% | -12.6% | -11.5% | -16.0% | -13.4% | -13.3% | |
| 0.4% | 0.9% | 0.1% | 0.1% | 0.2% | – | 0.2% | 0.2% | 0.2% | 0.7% | 0.2% | 0.2% | 0.3% | |
| -137.2% | -134.0% | -96.8% | -79.7% | -27.8% | -64.5% | -10.1% | -6.5% | -12.7% | -12.2% | -16.2% | -13.7% | -13.6% | |
| -113.2% | -122.1% | -70.5% | -79.6% | -2.1% | – | -10.0% | 2.3% | -12.6% | -7.3% | -16.0% | -11.7% | -11.7% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.